Remove 2004 Remove Conditions Remove Data Remove DEA
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

31) The United States DEA has stated that small amounts of other cannabinoids will also occur in all cannabis extracts, even those that purport to be CBD only – unless synthesized de novo, CBD isolate will always contain small amounts of THC when extracted from a plant. September 2004. 32: United States DEA. 30 (2): 187–96.(1998).

article thumbnail

Further Consideration of the STATES Act

Cannabis Law Report

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2003, 2004, 2007, 2008, Nov. 17, 2004 , 118 Stat. 6059, 6074, 6075, 6077(a), (b), 6253, Nov.

Banking 45